- Status:
- Topic prioritisation
- Technology type:
- Medicine
- Decision:
- Not selected
- Prioritisation programme:
- Medicines evaluation
- Rationale:
The NICE-Wide Prioritisation Board met on 29 April 2026 and concluded that an evaluation would not be appropriate for this product.
The 2024 voluntary scheme for branded medicines, pricing, access and growth states that NICE will continue to evaluate all new active substances and significant indications, except where there is a clear rationale not to do so. Decision makers have concluded that the clear rationale to not evaluate this product is due to it not being a new active substance, rather a direct replacement for TA246; that is prepared and formulated differently. In addition, the PB acknowledged that this product is widely used in clinical practice. Therefore, it was felt that an evaluation of these products would not provide any further value.
Email enquiries
If you have any queries please email topic.selection@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 29 April 2026 | Prioritisation board meeting |
For further information on how we select topics for development, please see our page about topic prioritisation